Literature DB >> 16236876

Optimal duration of IV and oral antibiotics in the treatment of thoracic actinomycosis.

JaeChol Choi1, Won-Jung Koh, Tae Sung Kim, Kyung Soo Lee, Joungho Han, Hojoong Kim, O Jung Kwon.   

Abstract

STUDY
OBJECTIVE: IV antibiotic therapy for 2 to 6 weeks followed by 6 to 12 months of oral antibiotic therapy is usually recommended for the treatment of thoracic actinomycosis. The objective of this study was to evaluate the duration of IV and oral antibiotic therapy for thoracic actinomycosis.
METHODS: We present a retrospective case series of 28 patients with thoracic actinomycosis as confirmed by histopathology from October 1994 through December 2003.
RESULTS: After diagnosis of actinomycosis, 54% (15 of 28 patients) received antibiotic therapy alone. The duration of IV antibiotic therapy ranged from 0 to 18 days (median, 2 days; interquartile range [IQR], 0 to 3 days), and the duration of oral antibiotic treatment ranged from 76 to 412 days (median, 167 days; IQR, 142 to 214 days) in patients who received antibiotics alone. Combination surgical and antibiotic therapy occurred in 46% (13 of 28 patients). The duration of IV antibiotic therapy ranged from 3 to 17 days (median, 8 days; IQR, 5 to 13 days), and the duration of oral antibiotic therapy ranged from 0 to 534 days (median, 150 days; IQR, 3.5 to 289 days) in these patients. Clinical cures were achieved in 96% (27 of 28 patients). There was no clinical evidence of recurrence during follow-up period at our hospital (median, 23 months; IQR, 9 to 44 months) in 21 patients, excluding 7 patients who were transferred to referring hospitals after completion of antibiotic therapy (n = 6) or during antibiotic therapy (n = 1).
CONCLUSIONS: Thoracic actinomycosis is best treated with individualized therapeutic modalities, depending on factors such as the initial burden of disease, the performance of resectional surgery, and the clinical and radiologic responses to therapy. The traditional recommendation of IV antibiotic therapy for 2 to 6 weeks followed by oral antibiotic therapy for 6 to 12 months is not always necessary for all thoracic actinomycosis patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236876     DOI: 10.1378/chest.128.4.2211

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  22 in total

1.  [Pulmonary mass suspected as malignant tumour. Thoracic wall abscess and fistula after pulmonary segmental resection].

Authors:  H Manner; R Henrich; N Manner; O Pech; M Nguyen-tat; B Weckler; C Ell
Journal:  Internist (Berl)       Date:  2008-08       Impact factor: 0.743

2.  Late complication after tropic storm accident: subcutaneous and intracranial actinomycetoma.

Authors:  Shyam B Verma; Suresh Nayak; Ravindra K Pasale; Thomas Kittner; Uwe Wollina
Journal:  Int Wound J       Date:  2008-09-19       Impact factor: 3.315

3.  Endobronchial actinomycosis secondary to foreign body aspiration.

Authors:  Chi Shao; Peng Wang; Ruie Feng; Xuefeng Sun
Journal:  Infection       Date:  2016-10-15       Impact factor: 3.553

4.  Actinomyces graevenitzii pulmonary abscess mimicking tuberculosis in a healthy young man.

Authors:  Smaranda Gliga; Mathilde Devaux; Marine Gosset Woimant; Dominique Mompoint; Christian Perronne; Benjamin Davido
Journal:  Can Respir J       Date:  2014 November/December       Impact factor: 2.409

5.  Pulmonary actinomycosis masquerading as lung cancer: Case letter.

Authors:  Moti Lal Bunkar; Prahlad Rai Gupta; Rajendra Takhar; Gajendra Singh Rajpoot; Savita Arya
Journal:  Lung India       Date:  2016 Jul-Aug

6.  Treatment of thoracic actinomycosis: A retrospective analysis of 40 patients.

Authors:  Jae-Uk Song; Hye Yun Park; Kyeongman Jeon; Sang-Won Um; O Jung Kwon; Won-Jung Koh
Journal:  Ann Thorac Med       Date:  2010-04       Impact factor: 2.219

7.  Differential diagnosis and treatment of periodontitis-mimicking actinomycosis.

Authors:  Nam Ryang Kim; Jun-Beom Park; Youngkyung Ko
Journal:  J Periodontal Implant Sci       Date:  2012-12-31       Impact factor: 2.614

8.  Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen.

Authors:  Janine Reichenbach; Uri Lopatin; Nizar Mahlaoui; Bojana Beovic; Ulrich Siler; Reinhard Zbinden; Reinhard A Seger; Louise Galmiche; Nicole Brousse; Samer Kayal; Tayfun Güngör; Stéphane Blanche; Steven M Holland
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

9.  Pulmonary actinomycosis during the first decade of 21st century: cases of 94 patients.

Authors:  So Ri Kim; Lae Young Jung; In-Jae Oh; Young-Chul Kim; Kyeong-Cheol Shin; Min Ki Lee; Sei-Hoon Yang; Hee Sun Park; Mi-Kyung Kim; Jin Young Kwak; Soo-Jung Um; Seung Won Ra; Woo Jin Kim; Seungsoo Kim; Eu-Gene Choi; Yong Chul Lee
Journal:  BMC Infect Dis       Date:  2013-05-14       Impact factor: 3.090

10.  An overview of thoracic actinomycosis: CT features.

Authors:  Ji-Yeon Han; Ki-Nam Lee; Jae Kyo Lee; Yun Hyeon Kim; Seok Jin Choi; Yeon Ju Jeong; Mee-Sook Roh; Pil Jo Choi
Journal:  Insights Imaging       Date:  2012-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.